• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by 180 Life Sciences Corp. (Amendment)

    2/7/22 4:30:32 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATNF alert in real time by email
    SC 13G/A 1 ea155010-13ga1nancha_180life.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    180 LIFE SCIENCES CORP.

     (Name of Issuer)

     

    COMMON STOCK, PAR VALUE $ 0.0001 PER SHARE

    (Title of Class of Securities)

     

    68236V104

    (CUSIP Number)

     

    December 31, 2021

     (Date of Event Which Requires Filing this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 68236V104 13G Page 2 of 5

     

    1  

    Name of Reporting Persons

     

    Jagdeep Nanchahal

    2  

    Check the Appropriate Box if a Member of a Group

    (see instructions)

    (a) ☐

    (b) ☐

    3  

    SEC Use Only

     

     

    4  

    Citizenship or Place of Organization

     

    British citizen

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person with:

      5  

    Sole Voting Power

     

    1,520,564

      6  

    Shared Voting Power

     

    -0-

      7  

    Sole Dispositive Power

     

    1,520,564

      8  

    Shared Dispositive Power

     

    -0-

    9  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,520,564

    10  

    Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)  ☐

     

     

    11  

    Percent of Class Represented by Amount in Row 9

     

    4.5%(1)

    12  

    Type of Reporting Person (see instructions)

     

    IN

      

    (1)Based on 34,016,456 shares of Common Stock of the Issuer outstanding as of November 12, 2021, as set forth on the cover page of the Issuer’s Quarter Report on Form 10-Q for the quarter ended September 30, 2021.

     

     

     

     

    CUSIP No. 68236V104 13G Page 3 of 5

     

    SCHEDULE 13G

     

    This Schedule 13G/A (Amendment No. 1)(this “Schedule 13G”) is being filed on behalf of Mr. Jagdeep Nanchahal, an individual, in connection with the common stock, $0.0001 par value per share (“Common Stock”) of 180 Life Sciences Corp., a Delaware corporation (the “Issuer”). Mr. Nanchahal is a consultant of the Issuer and the Chairman of the Issuer’s Clinical Advisory Board.

     

    Item 1(a) Name of Issuer.
       
      180 Life Sciences Corp.

     

    Item 1(b) Address of Issuer’s Principal Executive Offices.
       
     

    3000 El Camino Real, Bldg. 4, Suite 200

    Palo Alto, CA 94306

     

    Item 2(a) Name of Person Filing.
       
      Mr. Jagdeep Nanchahal
       
    Item 2(b) Address of Principal Business Office, or, if none, Residence.
       
      11 Terrett Avenue, Oxford, UK OX3 8FE

     

    Item 2(c) Citizenship or Place of Organization.

     

      Mr. Nanchahal is a British citizen.

     

    Item 2(d) Title of Class of Securities.
       
      Common stock, $0.0001 par value per share (the “Common Stock”).

     

    Item 2(e) CUSIP Number.
       
      68236V104

       

    Item 3 Reporting Person.

     

    If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

      

    (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

    (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

    (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

     

    (e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

    (f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

    (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

    (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

    (k) ☐ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

     

     

     

    CUSIP No. 68236V104 13G Page 4 of 5

       

    Item 4 Ownership.

     

    (a)Amount beneficially owned: Mr. Nanchahal is the beneficial owner of 1,520,564 shares of Common Stock.

     

    (b)Percent of class: Mr. Nanchahal is the beneficial owner of 4.5% of the outstanding shares of Common Stock of the Issuer. This percentage is determined by dividing 1,520,564, by 34,016,456 shares, the number of outstanding shares of the Issuer as of November 12, 2021.

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: 1,520,564

     

    (ii)shared power to vote or to direct the vote: -0-

     

    (iii)sole power to dispose or to direct the disposition of: 1,520,564

     

    (iv)shared power to dispose or to direct the disposition of: -0-

     

    Item 5 Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.

     

    Item 6 Ownership of More Than Five Percent on Behalf of Another Person.
       
      Inapplicable.

     

    Item 7 Identification and Classification of the Subsidiary which Acquired the Security Being Reported On by the Parent Holding Company.
       
      Inapplicable.

     

    Item 8 Identification and Classification of Members of the Group.
       
      Inapplicable.

     

    Item 9 Notice of Dissolution of Group.
       
      Inapplicable.

     

    Item 10 Certification.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    CUSIP No. 68236V104 13G Page 5 of 5

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 7, 2022

     

     

    /s/ Jagdeep Nanchahal

      Jagdeep Nanchahal

     

     

     

     

     

     

    Get the next $ATNF alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATNF

    DatePrice TargetRatingAnalyst
    9/15/2021$11.00Buy
    Maxim Group
    More analyst ratings

    $ATNF
    Financials

    Live finance-specific insights

    See more
    • 180 Life Sciences Corp. - Corporate Updates

      Announcing Acquisition of Advanced Gaming Technology Platform, Positive Progress on Legacy CBD Formulation, and Strengthened Balance SheetPALO ALTO, CA / ACCESSWIRE / October 3, 2024 / 180 Life Sciences Corp. (NASDAQ:ATNF) (the "Company" or "180") is pleased to provide a corporate update covering several key initiatives.CORPORATE UPDATE HIGHLIGHTS:Company shifts focus and enters global iGaming market - completes a significant technology acquisitionExpected Compliance with Nasdaq Listing Rule 5550(b)(1) - Company expects to meet Nasdaq continued listing requirement which requires maintenance of stockholders' equity of at least $2.5 millionPositive Study Results on CBD Pill Forms - 180 achieve

      10/3/24 8:30:00 AM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNF
    Leadership Updates

    Live Leadership Updates

    See more
    • 180 Life Sciences Corp. Regains Full Compliance with Nasdaq Continued Listing Rules

      PALO ALTO, CA / ACCESSWIRE / December 12, 2024 / 180 Life Sciences Corp. ("180" or the "Company") is pleased to announce that it has regained compliance with Nasdaq Listing Rule 5605(c)(2), which requires Nasdaq listed companies to maintain an audit committee consisting of three independent directors. This development follows the recent appointment of Mr. Stephen Shoemaker as an independent director of the Company and as a member of the Company's audit committee. With this appointment, 180 is now in full compliance with all Nasdaq continued listing requirements and has remedied all previously announced deficiencies.Mr. Blair Jordan, Interim CEO of the Company, stated, "This brings 180 into f

      12/12/24 8:00:00 AM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 180 Life Sciences Corp. Announces the Appointment of Stephen Shoemaker to Board of Directors

      PALO ALTO, CA / ACCESSWIRE / December 4, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF), a biotechnology company that is currently refocusing its business on the international entertainment and iGaming sector, today announced the appointment of Stephen Shoemaker to its Board of Directors, effective December 3, 2024.Mr. Shoemaker brings to 180 a wealth of experience as a seasoned senior executive and board member with a diverse background spanning finance, operations management, capital raising, and strategic planning. With over $2 billion in capital raised during his tenure in both CEO and CFO roles across four companies, Mr. Shoemaker has consistently demonstrated his

      12/4/24 8:00:00 AM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 180 Life Sciences Corp. Appoints Mr. Jay Goodman to Board of Directors

      PALO ALTO, CA / ACCESSWIRE / October 29, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF) today announced the appointment of Mr. Jay Goodman to its Board of Directors, effective immediately. Mr. Goodman brings over a decade of expertise in the software-as-a-service (SaaS) and iGaming industries, along with more than seven years of experience in executive leadership roles. Mr. Goodman's distinguished career includes contributions to several high-growth companies, successful IPOs, and extensive work in the Asia Pacific and Japan markets.Currently, Mr. Goodman serves as Sales Director for Asia Pacific and Japan at Docker, Inc., a position he has held since January 2024. Doc

      10/29/24 8:00:00 AM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNF
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 180 Life Sciences Corp. Announces Pricing of $2.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under NASDAQ Rules

      PALO ALTO, CA / ACCESSWIRE / December 27, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF), a biotechnology company that is currently refocusing its business on the international entertainment and iGaming sector, today announced that it has entered into a securities purchase agreement with several institutional investors to sell 1,200,000 shares of common stock in a registered direct offering priced at market under Nasdaq rules. In a concurrent private placement, the Company also agreed to issue unregistered warrants to purchase up to an aggregate of 1,200,000 shares of common stock. The combined effective offering price for each share of common stock and accompanying wa

      12/27/24 9:00:00 AM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 180 Life Sciences Corp. Regains Full Compliance with Nasdaq Continued Listing Rules

      PALO ALTO, CA / ACCESSWIRE / December 12, 2024 / 180 Life Sciences Corp. ("180" or the "Company") is pleased to announce that it has regained compliance with Nasdaq Listing Rule 5605(c)(2), which requires Nasdaq listed companies to maintain an audit committee consisting of three independent directors. This development follows the recent appointment of Mr. Stephen Shoemaker as an independent director of the Company and as a member of the Company's audit committee. With this appointment, 180 is now in full compliance with all Nasdaq continued listing requirements and has remedied all previously announced deficiencies.Mr. Blair Jordan, Interim CEO of the Company, stated, "This brings 180 into f

      12/12/24 8:00:00 AM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 180 Life Sciences Corp. Announces the Appointment of Stephen Shoemaker to Board of Directors

      PALO ALTO, CA / ACCESSWIRE / December 4, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF), a biotechnology company that is currently refocusing its business on the international entertainment and iGaming sector, today announced the appointment of Stephen Shoemaker to its Board of Directors, effective December 3, 2024.Mr. Shoemaker brings to 180 a wealth of experience as a seasoned senior executive and board member with a diverse background spanning finance, operations management, capital raising, and strategic planning. With over $2 billion in capital raised during his tenure in both CEO and CFO roles across four companies, Mr. Shoemaker has consistently demonstrated his

      12/4/24 8:00:00 AM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Woody James N. bought $4,700 worth of shares (25,000 units at $0.19), increasing direct ownership by 60% to 66,888 units (SEC Form 4)

      4 - 180 Life Sciences Corp. (0001690080) (Issuer)

      12/18/23 4:15:16 PM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Jordan Blair acquired 1,318,000 shares (SEC Form 4)

      4 - 180 Life Sciences Corp. (0001690080) (Issuer)

      4/30/25 5:57:06 PM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Elray Resources, Inc. converted options into 1,318,000 shares (SEC Form 4)

      4 - 180 Life Sciences Corp. (0001690080) (Issuer)

      4/11/25 6:05:04 PM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Jordan Blair acquired 200,000 shares (SEC Form 4)

      4 - 180 Life Sciences Corp. (0001690080) (Issuer)

      4/2/25 4:59:04 PM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNF
    SEC Filings

    See more
    • SEC Form S-3 filed by 180 Life Sciences Corp.

      S-3 - 180 Life Sciences Corp. (0001690080) (Filer)

      5/9/25 4:15:31 PM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by 180 Life Sciences Corp.

      10-K/A - 180 Life Sciences Corp. (0001690080) (Filer)

      5/8/25 4:20:24 PM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 180 Life Sciences Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - 180 Life Sciences Corp. (0001690080) (Filer)

      5/1/25 9:18:16 AM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by 180 Life Sciences Corp.

      SC 13G/A - 180 Life Sciences Corp. (0001690080) (Subject)

      11/14/24 3:53:30 PM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by 180 Life Sciences Corp.

      SC 13G - 180 Life Sciences Corp. (0001690080) (Subject)

      10/18/24 5:00:02 PM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by 180 Life Sciences Corp.

      SC 13G - 180 Life Sciences Corp. (0001690080) (Subject)

      2/14/24 3:27:19 PM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on 180 Life Sciences Corp. with a new price target

      Maxim Group initiated coverage of 180 Life Sciences Corp. with a rating of Buy and set a new price target of $11.00

      9/15/21 7:48:59 AM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care